We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$14B
$72.3M 1.02%
3,047,500
-927,900
-23% -$21.5M
FATE icon
27
Fate Therapeutics
FATE
$284M
$67.3M 0.95%
1,961,400
+398,200
+25% +$11.9M
CNC icon
28
Centene
CNC
$31.6B
$66.3M 0.94%
1,042,747
+232,477
+29% +$15.1M
CRL icon
29
Charles River Laboratories
CRL
$11B
$63.8M 0.9%
365,833
+34,210
+10% +$5.46M
CI icon
30
Cigna
CI
$76B
$63.2M 0.89%
336,726
-12,563
-4% -$2.38M
BSX icon
31
Boston Scientific
BSX
$65.1B
$60.8M 0.86%
1,730,620
+189,395
+12% +$6.82M
BDTX icon
32
Black Diamond Therapeutics
BDTX
$101M
$59.1M 0.84%
1,403,000
+73,000
+5% +$2.69M
SAGE
33
DELISTED
Sage Therapeutics
SAGE
$58.9M 0.83%
1,415,504
-2,600
-0.2% -$94.4K
BDX icon
34
Becton Dickinson
BDX
$42.7B
$58.8M 0.83%
252,089
-1,152
-0.5% -$278K
CRSP icon
35
CRISPR Therapeutics
CRSP
$4.6B
$58.8M 0.83%
800,462
– –
SYK icon
36
Stryker
SYK
$125B
$58.4M 0.83%
323,942
+151,229
+88% +$27.9M
EW icon
37
Edwards Lifesciences
EW
$50.4B
$54.7M 0.77%
791,682
+89,787
+13% +$6.38M
BAX icon
38
Baxter International
BAX
$11.4B
$53.9M 0.76%
625,495
+33,574
+6% +$2.92M
ARVN icon
39
Arvinas
ARVN
$519M
$53.1M 0.75%
1,581,703
+312,400
+25% +$13.3M
SRRK icon
40
Scholar Rock
SRRK
$5.82B
$50M 0.71%
2,746,106
+31,000
+1% +$528K
MTEM
41
DELISTED
Molecular Templates, Inc.
MTEM
$48M 0.68%
231,816
+37,773
+19% +$8.78M
HRC
42
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$46.3M 0.65%
421,294
+125,815
+43% +$13.2M
PODD icon
43
Insulet
PODD
$11B
$45M 0.64%
231,749
+129,399
+126% +$24.7M
GWPH
44
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$42.9M 0.61%
349,566
+98,600
+39% +$11.2M
DXCM icon
45
DexCom
DXCM
$27.1B
$41.6M 0.59%
410,820
+5,508
+1% +$493K
CDNA icon
46
CareDx
CDNA
$1.95B
$41.3M 0.59%
1,166,839
-110,212
-9% -$3.14M
INSM icon
47
Insmed
INSM
$23.1B
$40.1M 0.57%
1,456,174
-157,296
-10% -$3.73M
AMGN icon
48
Amgen
AMGN
$203B
$39.6M 0.56%
167,963
+36,390
+28% +$8.3M
BIO icon
49
Bio-Rad Laboratories Class A
BIO
$8.38B
$36.1M 0.51%
79,871
+17,498
+28% +$7.72M
EVH icon
50
Evolent Health
EVH
$507M
$35.8M 0.51%
5,028,363
+447,905
+10% +$3M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.